CN Patent

CN116751161A — 喹啉类化合物及其制备方法、药物组合物及医药用途

Assigned to Academy of Military Medical Sciences AMMS of PLA · Expires 2023-09-15 · 3y expired

What this patent protects

本发明属于医药领域，具体涉及式(I)所示的化合物、其药学可接受的盐、前药、稳定同位素衍生物、异构体、溶剂化物或多晶型物；还涉及化合物的制备方法、包含上述化合物的药用组合物、它们的医药用途。本发明化合物可阻断VEGF/VEGFR通路，能够预防或治疗与VEGF/VEGFR通路有关的疾病，例如显著抑制VEGF等蛋白激酶活性，具有抗肿瘤活性。

USPTO Abstract

本发明属于医药领域，具体涉及式(I)所示的化合物、其药学可接受的盐、前药、稳定同位素衍生物、异构体、溶剂化物或多晶型物；还涉及化合物的制备方法、包含上述化合物的药用组合物、它们的医药用途。本发明化合物可阻断VEGF/VEGFR通路，能够预防或治疗与VEGF/VEGFR通路有关的疾病，例如显著抑制VEGF等蛋白激酶活性，具有抗肿瘤活性。

Drugs covered by this patent

Patent Metadata

Patent number
CN116751161A
Jurisdiction
CN
Classification
—
Expires
2023-09-15
Drug substance claim
No
Drug product claim
No
Assignee
Academy of Military Medical Sciences AMMS of PLA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.